{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/ORIC/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-15T08:40:05.462Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":4475,"canonical_name":"Oric Pharmaceuticals, Inc.","cik":"0001796280","uei":null,"lei":null,"duns":null,"ticker":"ORIC"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":16},"count":16,"timeline":[{"ts":"2026-09-28","kind":"sec.insider.13400","reporter":"Piscitelli Dominic","title":"Chief Financial Officer","shares":13400,"price_per_share":13.5267,"usd_value":181258,"security_title":"Common Stock","importance":15.18125778},{"ts":"2026-09-28","kind":"sec.insider.13400","reporter":"Piscitelli Dominic","title":"Chief Financial Officer","shares":13400,"price_per_share":4.36,"usd_value":58424,"security_title":"Common Stock","importance":15.058424},{"ts":"2026-08-03","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Oric Pharmaceuticals, Inc. — 2026-08-03","url_slug":"/sec/cik-0001796280/10-q/0001193125-26-330631","accession_number":"0001193125-26-330631","importance":45},{"ts":"2026-08-03","kind":"sec.filing","form_type":"8-K","title":"8-K — Oric Pharmaceuticals, Inc. — 2026-08-03","url_slug":"/sec/cik-0001796280/8-k/0001193125-26-330568","accession_number":"0001193125-26-330568","importance":35},{"ts":"2026-07-30","kind":"sec.filing","form_type":"8-K","title":"8-K — Oric Pharmaceuticals, Inc. — 2026-07-30","url_slug":"/sec/cik-0001796280/8-k/0001193125-26-326309","accession_number":"0001193125-26-326309","importance":35},{"ts":"2026-07-30","kind":"sec.filing","form_type":"S-8","title":"S-8 — Oric Pharmaceuticals, Inc. — 2026-07-30","url_slug":"/sec/cik-0001796280/s-8/0001193125-26-326363","accession_number":"0001193125-26-326363","importance":30},{"ts":"2026-07-24","kind":"sec.insider.s","reporter":"Heyman Richard A.","title":"","shares":7000,"price_per_share":12.02,"usd_value":84140,"security_title":"Common Stock","importance":35.08414},{"ts":"2026-07-24","kind":"sec.insider.s","reporter":"Heyman Richard A.","title":"","shares":6100,"price_per_share":12.02,"usd_value":73322,"security_title":"Common Stock","importance":35.073322},{"ts":"2026-07-24","kind":"sec.insider.m","reporter":"Heyman Richard A.","title":"","shares":3500,"price_per_share":1.6,"usd_value":5600,"security_title":"Common Stock","importance":15.0056},{"ts":"2026-07-06","kind":"sec.form144","reporter":"Richard A, Heyman","title":"Director","shares":7000,"usd_value":84000,"security_title":"Common","approx_sale_date":"2026-07-06","accession_number":"0001968582-26-000699","importance":40.0168},{"ts":"2026-07-06","kind":"sec.form144","reporter":"Richard A, Heyman","title":"Director","shares":6400,"usd_value":76800,"security_title":"Common","approx_sale_date":"2026-07-06","accession_number":"0001968582-26-000698","importance":40.01536},{"ts":"2026-07-06","kind":"sec.insider.s","reporter":"Heyman Richard A.","title":"","shares":300,"price_per_share":12,"usd_value":3600,"security_title":"Common Stock","importance":35.0036},{"ts":"2026-06-22","kind":"sec.filing","form_type":"8-K","title":"8-K — Oric Pharmaceuticals, Inc. — 2026-06-22","url_slug":"/sec/cik-0001796280/8-k/0001193125-26-277511","accession_number":"0001193125-26-277511","importance":35},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Oric Pharmaceuticals, Inc. — 2026-05-15","url_slug":"/sec/cik-0001796280/schedule-13g/0000080255-26-000420","accession_number":"0000080255-26-000420","importance":55},{"ts":"2026-05-12","kind":"sec.13dg","reporter":"Oric Pharmaceuticals, Inc.","shares":3442940,"percent_of_class":3.3,"security_title":"SCHEDULE 13G/A","accession_number":"0000078003-26-000067","excerpt":null,"importance":55},{"ts":"2026-05-12","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Oric Pharmaceuticals, Inc. — 2026-05-12","url_slug":"/sec/cik-0001796280/schedule-13g-a/0000078003-26-000067","accession_number":"0000078003-26-000067","importance":30}]}